With sepsis, every hour counts
Target therapy sooner, with species identification before the second dose of empiric therapy
LEARN MORE

The first and only FDA-cleared diagnostic tests to provide species identification of sepsis-causing bacterial and fungal pathogens, directly from a whole blood sample and independent of a positive blood culture.

T2Candida Case Study
Secondary Candidemia in Critically Ill COVID-19 Patient
READ CASE STUDY

T2Candida enabled the detection of candidemia 29 hours before a positive blood culture was returned. Early detection allowed for the rapid initiation of antifungal therapy in a critically ill COVID-19 patient.

Enhancing the standard of care.

With T2 Biosystems, hospitals can identify sepsis-causing pathogens faster and more accurately than the standard of blood culture alone

Hospitals trust in T2MR Technology

UPMC
Demonstrated 47% reduction in antifungal therapy.
Henry Ford Health System
Realized 7 days reduction in median length of stay in the ICU.
Lee Health
T2Bacteria positive results 20 hours sooner than blood culture.
Huntsville Hospital
Saved ~$280 pharmacy costs per patient.
Robert Wood Johnson Medical School
Identified escalation and de-escalation opportunities in patients tested with T2Candida.
Riverside Community Hospital
100% of patients who tested positive received appropriate therapy in <9 hours

Patient Case Studies

Real stories about the positive impact of T2 Biosystems on clinical decisions and outcomes

Numbers don't lie.

Sepsis is a burden on healthcare and patients, contributing to:

1 in 2-3
US hospital deaths.
11 million
deaths annually, worldwide.
$62 billion
in US healthcare costs.
Integrate T2 Biosystems panels into your hospital today!